Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting

Cytotherapy

Volumn 7, Issue 2, 2005, Pages 126-133

  Le, N T ^a   Chen, B J ^a   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allodepletion; Memory T cells; Naive T cells; Photodynamic cell purging; Stem cell transplantation

Indexed keywords

4,5 DIBROMORHODAMINE METHYL ESTER; ALLOANTIGEN; PHOTOSENSITIZING AGENT; RHODAMINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CELL MATURATION; CELL SELECTION; CELL TRANSFER; CYTOTOXICITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG MECHANISM; DRUG STRUCTURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; HOST CELL; HUMAN; IMMUNE RESPONSE; INCIDENCE; LYMPHOCYTE FUNCTION; MEDICAL DOCUMENTATION; MEMORY CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; RELAPSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STRUCTURE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 21044433036     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240510018163     Document Type: Review

References (26)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38.
2. Kernan NA. T-cell depletion for prevention of graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, eds Bone Marrow Transplantation. Boston, MA: Blackwell, 1994: 124-35.
3. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compare with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986;314:729-35.
4. Beatty PG. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992;19: 13-9.
5. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990;4:687-98.
6. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-64.
7. van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lympho-proliferative disease following T-cell-depleted SCT. Blood 2001;98:972-8.
8. Zeiser R, Marks R, Bertz H et al. Immunopathogenesis of acute graft-versus-host disease: implications of novel preventive and therapeutic strategies. Ann Hemtol 2004;83:551-65.
9. Pal P, Zeng H, Durocher G et al. Phototoxicity of some bromine-substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers. Photochem Photobiol 1996;63:161-8.
10. Villeneuve L. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem 1999;30:1-17.
11. Roy DC, Boileau J, Laplante J et al. Phase I study of autologous progenitor cell transplantation (PCT) purged with a photodynamic approach for patients with chronic myeloid leukemia (CML). Blood 2000;96(suppl 1):583a.
12. Roy DC, Dallaire N, Moreau B et al. Photodynamic therapy (PDT) of B-lineage non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2000;96(suppl 1):185a.
13. Guimond M, Balassy A, Barrette M et al. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 2002;100:375-82.
14. Guimond M, Brochu S, Perreault C et al. Specific elimination of anti-host T cell alloreactivity using a photodynamic approach. FASEB J 2000;14:1074.
15. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002;99:3083-8.
16. Suchin EJ, Langmuir PB, Palmer E et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001;166:973-81.
17. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004;103:1158-65.
18. Amrolia PJ, Muccioli-Casadei G, Yvon E et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003;102:2292-9.
19. 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Translational Med 2003;1:14-23.
20. Sabin S, Akoglu TF, Gurbuz O et al. Reevaluation of skin-explant model in graft-versus-host disease prediction. Clin Transplant 1995;9:370-4.
21. Dickinson AM, Cavet J, Cullup H et al. GvHD risk assessment in hematopoietic stem cell transplantation: role of cytokine gene polymorphisms and an in vitro human skin explant model. Hum Immunol 2001;62:1266-76.
22. Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-7.
23. - Memory T cells without graft-versus-host disease. Blood 2004;103:1534-41.
24. + T cells do not induce graft-versus-host disease. J Clin Invest 2003;112:101-8.
25. + naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004;104:2403-9.
26. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.